Rising prevalence of sleep related neurological disorders is driving the market for narcolepsy over the forecast period.

 

According to a new market research study titled 'Narcolepsy Market - Global Analysis and Forecasts by Type, Product and Distribution Channel, the global narcolepsy market is expected to reach US$ 4,537.9 Mn in 2027 from US$ 2,026.8 Mn in 2018. The market is estimated to grow with a CAGR of 9.5% from 2019-2027. The report highlights the trends prevalent in the global narcolepsy market and the factors driving the market along with those that act as deterrents to its growth.

 

The narcolepsy market by type is segmented into narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary cataplexy. In 2018, the narcolepsy with cataplexy segment held a largest market share of 65.1% of the narcolepsy market, by type. This segment is also expected to dominate the market in 2027 owing to its significant prevalence among patients suffering with narcolepsy. Episodes of cataplexy are reported to be encountered among 55-60% of patients suffering with narcolepsy. Moreover, the similar segment is anticipated to also witness the fastest growth rate of 9.7% during the forecast period, 2019 to 2027 owing to the increasing demand for drugs to treat the disease.

 

Key factors driving the market are rising prevalence of sleep related disorders, emerging local pharmaceutical & biopharmaceutical companies, and increasing awareness regarding neurological disorders. However, factors such as side effects and risks associated with narcolepsy medications and delayed diagnosis or misdiagnosis of narcolepsy are likely to restrain the market growth to a certain extent.

 

Some of the prominent players operating in narcolepsy market are Bioprojet, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., Graymark Healthcare, Inc., Arena Pharmaceuticals, Inc., Shire (Acquired by Takeda), Ligand Pharmaceuticals, Inc., Novartis AG, Mylan N.V., and Shionogi Inc. The market players are focused towards bringing new and innovative products and services to sustain their position in the market. For instance, in October, 2018, Officials with the FDA have approved Jazz Pharmaceuticals' Xyrem (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness in pediatric patients aged 7 to 17 years with narcolepsy. The drug had previously been approved for use in adult patients. The developments performed by the companies are helping the market to grow in the coming years.


The report segments the global narcolepsy market as follows:

Global Narcolepsy Market - By Type

  • Narcolepsy with Cataplexy
  • Narcolepsy without Cataplexy
  • Secondary Cataplexy
Global Narcolepsy Market – By ProductSodium Oxybate
  • Central Nervous System (CNS) Stimulants
  • Antidepressants
Global Narcolepsy Market – By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies         
Global Narcolepsy Market – By Geography
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific (APAC)
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Middle East & Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
  • South & Central America (SCAM)
    • Brazil
    • Argentina

Contact Us

Contact Person: Sameer Joshi

Phone: +1-646-491-9876

Email Id: sales@theinsightpartners.com